In This Article:
As the broader European markets face heightened uncertainty due to rising inflation and cautious central bank policies, Sweden's market dynamics offer a unique landscape for investors focusing on growth companies with high insider ownership. Such firms often demonstrate a strong alignment between shareholders' interests and management, which can be particularly appealing in turbulent times. In this context, understanding the intrinsic qualities that contribute to the resilience and potential of these companies becomes crucial. High insider ownership can signal confidence in the company’s prospects from those who know it best—its leaders.
Top 10 Growth Companies With High Insider Ownership In Sweden
Name | Insider Ownership | Earnings Growth |
CTT Systems (OM:CTT) | 16.9% | 21.6% |
BioArctic (OM:BIOA B) | 35.1% | 50.5% |
Sileon (OM:SILEON) | 33.3% | 109.3% |
InCoax Networks (OM:INCOAX) | 18% | 104.9% |
KebNi (OM:KEBNI B) | 37.8% | 90.4% |
Calliditas Therapeutics (OM:CALTX) | 11.6% | 53% |
edyoutec (NGM:EDYOU) | 14.6% | 63.1% |
Egetis Therapeutics (OM:EGTX) | 17.6% | 98.2% |
Yubico (OM:YUBICO) | 37.5% | 42.5% |
SaveLend Group (OM:YIELD) | 24.9% | 103.4% |
We're going to check out a few of the best picks from our screener tool.
Medicover
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Medicover AB operates in the healthcare and diagnostic services sector, serving regions including Poland and Sweden, with a market capitalization of approximately SEK 29.81 billion.
Operations: The revenue for the company is primarily generated through Healthcare Services at €1.26 billion and Diagnostic Services at €585.20 million.
Insider Ownership: 11.1%
Medicover, a Swedish growth company with significant insider ownership, has demonstrated robust earnings growth of 1492.9% over the past year and is expected to continue this trend with forecasts showing a 38.2% annual increase. Despite challenges in covering interest payments with earnings and large one-off items impacting financial results, Medicover trades at 51% below estimated fair value. Recent corporate guidance anticipates organic revenue exceeding €2.2 billion by year-end 2025, highlighting its potential amidst a competitive market landscape where it outpaces average Swedish market growth rates in both revenue and earnings.
-
Dive into the specifics of Medicover here with our thorough growth forecast report.
-
Our expertly prepared valuation report Medicover implies its share price may be too high.
Pandox
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pandox AB is a hotel property company that specializes in owning, operating, and leasing hotel properties, with a market capitalization of approximately SEK 34.86 billion.